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cisplatin for the 4th administration only. Our results sug-
gest that subclinical doses (15 and 18 mg/m2) of cisplatin 
induce nausea-like behavior and emesis but have reduced 
adverse effects compared with the clinical dose allowing 
for repeated administration in crossover studies.
Keywords Nausea · Emesis · cisplatin · Neutropenia · 
Nephrotoxicity · arginine vasopressin · cortisol
Introduction
the development of a low-dose model of nausea and 
emesis in the dog has obvious uses within the field of vet-
erinary medicine but also in clinical drug development for 
human medicine. the dog is close to man in emetic sen-
sitivity (andrews et al. 1990; Percie du sert et al. 2012), 
and a canine model of nausea and validated biomarkers 
of nausea would have use for preclinical testing of novel 
anti-nausea compounds and for assessing the emetic 
liability of novel medicines within the pharmaceutical 
industry.
Nausea is a subjective experience, which cannot be eas-
ily be quantified. Identification of a biomarker would allow 
for the quantifiable measurement of this subjective sensa-
tion. Potential biomarkers of nausea, arginine vasopressin 
(aVP) and cortisol were identified from the literature. aVP 
is released in response to fluid loss from vomiting (Koch 
1997) and is known to be greatly increased, in man and 
dogs following cancer chemotherapy agents (Fisher et al. 
1982; cubeddu et al. 1990). cortisol has been found in 
humans to be reduced following cisplatin treatment (Mor-
row et al. 2002), and patients with low urinary cortisol 
experience significantly higher nausea scores (Fredrikson 
et al. 1992).
Abstract  cisplatin is a highly emetogenic cancer chem-
otherapy agent, which is often used to induce nausea and 
emesis in animal models. the cytotoxic properties of cis-
platin also cause adverse events that negatively impact on 
animal welfare preventing repeated administration of cispl-
atin. In this study, we assessed whether a low (subclinical) 
dose of cisplatin could be utilized as a model of nausea and 
emesis in the dog while decreasing the severity of adverse 
events to allow repeated administration. the emetic, nau-
sea-like behavior and potential biomarker response to both 
the clinical dose (70 mg/m2) and low dose (15 mg/m2) of 
cisplatin was assessed. Plasma creatinine concentrations 
and granulocyte counts were used to assess adverse effects 
on the kidneys and bone marrow, respectively. Nausea-like 
behavior and emesis was induced by both doses of cispl-
atin, but the latency to onset was greater in the low-dose 
group. No significant change in plasma creatinine was 
detected for either dose groups. Granulocytes were signif-
icantly reduced compared with baseline (P = 0.000) fol-
lowing the clinical, but not the low-dose cisplatin group. 
tolerability of repeated administration was assessed with 
4 administrations of an 18 mg/m2 dose cisplatin. Plasma 
creatinine did not change significantly. cumulative effects 
on the granulocytes occurred, they were significantly 
decreased (P = 0.03) from baseline at 3 weeks following 
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General consensus is that due to the subjective nature 
of nausea, it can only be truly studied in humans who are 
able to verbalize the feeling (andrews and sanger 2014). 
however, behaviors suggestive of nausea and autonomic 
changes, such as salivation, which accompany nausea in 
humans, have been identified in animals including the 
dog (chen et al. 2003; de la Puente-Redondo et al. 2007; 
Yu et al. 2009). Due to these limitations of animal models, 
we will use the term “nausea-like behavior” to describe the 
experience in the dog.
cisplatin is a platinum-based cytotoxic drug used in 
both human and veterinary cancer chemotherapy (Kelland 
2007; Barabas et al. 2008). Due to its highly emetogenic 
properties, cisplatin has been widely utilized as a tool to 
induce acute nausea and vomiting in preclinical animal 
models, lasting approximately 6 h in the dog (de la Puente-
Redondo et al. 2007).
cisplatin acts via both peripheral and central pathways to 
induce emesis (Minami et al. 2003). the peripheral mecha-
nism of cisplatin is thought to be initiated by 5-ht release 
in the gastrointestinal system. 5-ht stimulates abdominal 
vagal afferents, which project to emetic brainstem regions. 
sectioning of the dorsal and vagal trunks greatly reduced 
the emetic response to cisplatin (andrews et al. 1990). cis-
platin itself or factors released into the bloodstream due to 
cell damage caused by cisplatin (cubeddu 1992) act cen-
trally to stimulate the area postrema, also referred to as 
the ‘chemoreceptor trigger zone’. the emetic stimulus is 
relayed from the area postrema to the ‘vomiting center’ in 
the nucleus tractus solitaries, which acts as a central pattern 
generator to coordinate the emetic reflex (andrews et al. 
1988; horn 2008). the mechanisms by which cisplatin 
induces nausea are not well characterized. the subjective 
nature of nausea and lack of animal models has hindered 
the identification of these mechanisms.
the clinical dose of cisplatin for the treatment of cancer 
in dogs is 70 mg/m2 administered every 3–4 weeks (Ram-
sey 2012). cisplatin treatment is associated with numerous 
adverse effects including nephrotoxicity, myelotoxicity, 
ototoxicity and neurotoxicity (Barabas et al. 2008). the 
toxic effects of cisplatin were assessed in healthy dogs; it 
has a cumulative effect with significant toxicity developing 
after 4 administrations of cisplatin (Ogilvie et al. 1992).
Development of a model of nausea and emesis utilizing 
a subclinical dose of cisplatin would fulfill the reduction 
and refinement objectives of the 3 R (reduction, replace-
ment and refinement) principles of in vivo research (Russell 
et al. 1959). Model refinement occurs from the identifica-
tion of a dose, which does not induce the toxicities associ-
ated with cisplatin treatment. Refinement of the model to 
identify a dose that is safe enough for repeated administra-
tion will reduce the number of animals required for experi-
mentation as crossover studies, rather than parallel studies, 
can be carried out where each animal can act as its own 
control increasing the statistical power of the study. Experi-
ments by Ito et al. (1987) showed that subclinical doses of 
cisplatin as low as 0.42 mg/kg equivalent to approximately 
8 mg/m2 can induce a response of 3–7 emetic events in the 
dog. the maximal effect of 11–13 emetic events occurred 
at 0.85 mg/kg which is equivalent to 15–18 mg/m2 cisplatin 
(depending on the weight of the dog) and was not increased 
at higher doses, up to 2.4 mg/kg (which is equivalent to 
43–53 mg/m2).
low doses of cisplatin have been employed for can-
cer treatment in humans in combination with other anti-
cancer agents. the incidence of nausea and vomiting has 
been reported in 90 % of patients receiving 15 mg/m2 
cisplatin (samson et al. 1984), prior to the development 
of modern anti-emetics. More recently, 54 % of patients 
receiving 4 mg/m2 cisplatin (Ina et al. 2008) and 75 % of 
patients receiving 10 mg/m2 cisplatin (Imamura et al. 2006) 
reported nausea and vomiting.
the objectives of the present study were firstly to find a 
safe repeatable dose of cisplatin which induces significant 
nausea-like behavior. secondly the study aimed to inves-
tigate the validity of potential “nausea” biomarkers in the 
dog.
Methods
animals
animal procedures undertaken were approved by the UK 
home Office animals (scientific Procedures) act 1986 
(asPa), Project license 70/7269 with ethical approval of 
the Royal Veterinary college (RVc) Ethics and Welfare 
committee. Eight healthy spayed Beagle dogs (Marshall 
Farms, North Rose, NY, Usa), four male and four females 
weighing from 6.5 to 11.5 kg, aged 1.5 years at the start 
of the studies, were utilized. Dogs were group housed 
according to sex on a 12-h light/dark cycle and fed canine 
lab diet 5007 (IPs ltd, london, UK) once daily (100–
200 g adjusted as needed to maintain ideal weight); water 
was available ad libitum. the dogs were discharged from 
asPa and re-homed as pets at the end of the study with the 
approval of the RVc’s Named Veterinary surgeon.
Experimental design
Study 1 (clinical versus low‑dose cisplatin)
the clinical dose of cisplatin (70 mg/m2) was compared 
with a subclinical dose (15 mg/m2), which corresponds to 
the lower limit of the 0.84 mg/kg emetic dose identified by 
Ito et al. (1987). this was a 2-period study blocked by sex 
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and by day, a 28-day washout period was observed between 
the two doses of cisplatin. In period 1, dogs were randomly 
allocated to treatment with the clinical dose (70 mg/m2) 
cisplatin (hospira, leamington spa, UK) (n = 4) or 0.9 % 
saline placebo (n = 4). In period 2, dogs that received 
placebo treatment in period 1 were treated with low-dose 
(15 mg/m2) cisplatin (n = 4) and dogs that received cispl-
atin treatment in period 1 were treated with 0.9 % saline 
placebo (n = 4).
Study 2 (repeated low‑dose cisplatin administration)
as a part of a separate study, the same 8 dogs from study 
1 received repeated administrations of 18 mg/m2, the 
upper limit of the 0.84 mg/kg emetic dose identified by 
Ito et al. (1987). cisplatin was administered in each of the 
4 periods of the study (cumulative dose of 72 mg/m2), at 
least 28-days washout was observed between cisplatin 
administrations.
Operator safety
cisplatin was dispensed with the medical closed system 
(BD Phaseal, Oxford, UK) under a cytotoxic fume hood. 
appropriate personal protective equipment (PPE) was 
worn by users when handling cisplatin and contaminated 
waste. Dogs were quarantined for 10 days following cis-
platin treatment, PPE was worn to handle dogs, and all 
waste was considered to be contaminated with cytotoxic 
material.
Jugular vein catheter placement
One day prior to cisplatin administration, a double lumen 
jugular vein catheter (JVc) was implanted under general 
anesthesia using the modified seldinger technique (Por-
tillo et al. 2006). Dogs were sedated with medetomidine 
(0.01 mg/kg, Medetor, Virbac ltd, Bury st Edmunds, UK) 
and butorphanol (0.2 mg/kg, Dolorex MsD animal health, 
Milton Keynes, UK) both administered by intramuscu-
lar injection (i.m). anesthesia was induced by intrave-
nous administration of propofol (PropoFlo Plus Emulsion 
for injection, abbott animal health, Maidenhead, UK) to 
effect and maintained by inhalation of isoflurane (IsoFlo 
100 % w/w inhalation vapor, abbott animal health) car-
ried in oxygen. at the end of the procedure, inhalation 
anesthesia was withdrawn and sedation reversed by atipam-
ezole administered i.m. (0.005 mg/kg; Revertor, Virbac). 
analgesia was provided with medetomidine and butorph-
anol during the transcutaneous catheterization, but due to 
the noninvasive nature of the procedure, analgesia was not 
repeated on recovery.
Fluid treatment
the time of initiation of cisplatin infusion was measured 
in hours and defined as t0h (Fig. 1). For both study 1 and 
2, all dogs were given 0.9 % saline and mannitol infusions 
to reduce the nephrotoxic effects of cisplatin (Ogilvie et al. 
1988) (Fig. 1). a solution of 0.9 % saline (Baxter, New-
bury, UK) was infused at 25 ml/kg/h−1 for 3 h (from time 
t-3h to t0h) via the first lumen of the JVc prior to cisplatin 
administration. Mannitol (0.5 mg/kg i.v.; Baxter, Newbury, 
UK) was infused through a 0.22-µm filter over a 15-min 
period from t−0.5h prior to the start of cisplatin administra-
tion. after cisplatin administration, a total volume of 0.9 % 
saline equal to 20 ml/kg was administered as i.v. boluses 
via the JVc at hourly intervals over 6 h following cisplatin 
treatment.
cisplatin administration
Study 1: at t0h, dogs received treatment with 70, 15 mg/
m2 or 0.9 % saline placebo (Fig. 1). Dogs were weighed 
on the day preceding the injection. For both doses of cis-
platin, the appropriate volume of 1 mg/ml cisplatin solu-
tion for each dog was diluted in 0.9 % saline to produce 
a standard volume of 40 ml. the diluted cisplatin solu-
tion was administered through the second lumen of the 
JVc using automatic dispensing syringe at a flow rate of 
2.0 ml/min−1.
Study 2: cisplatin was repeatedly administered intra-
venously at the dose of 18 mg/m2 to all dogs as described 
above during each of the 4 periods of the study. a washout 
time of 28 days was observed between periods.
Fig. 1  Fluid and cisplatin administration protocol common to study 
1 (high- vs. low-dose cisplatin) and study 2 (4-period repeated low-
dose cisplatin administration)
2688 Exp Brain Res (2014) 232:2685–2697
1 3
Behavioral assessment
Prior to the commencement of studies, an acclimatization 
period of 1 month was allowed for the dogs to become 
familiar with the experimental context. During this period, 
the observer became accustomed to the dogs normal behav-
ior, which was used as a baseline reference for behavio-
ral observations carried out in study 1. During the 28-day 
washout interval between the periods of the study, the dogs 
were placed in the experimental context weekly to prevent 
the development of a conditioned response.
Observations of behaviors suggestive of a nausea-
like state and the number of vomits were recorded for 
6–7 h following cisplatin treatment for study 1. Nausea 
was recorded by a single trained observer using a visual 
analogue scale (Vas) on a line from 0 to 100 mm (de la 
Puente-Redondo et al. 2007). the observer makes a judg-
ment on the severity of the dog’s nausea-like behaviors 
based on the presence and frequency of one or more of the 
following during a 15-min time bin; salivation, lip licking, 
lethargy, restlessness or turning/circling behavior signaling 
that vomiting is imminent. a score of 0 mm indicates ‘No 
“Nausea”’ and a score of 100 mm indicates ‘Worst pos-
sible “Nausea”’. the observer was blinded to treatment 
allocation.
Blood sampling
Venous blood samples were collected from the jugular vein 
catheter at t = −24 (baseline), 0, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 
4, 5, 6, 7 (for low dose only) and 24 h following cisplatin 
administration. approximately 5 ml of blood was taken at 
each time point and collected into EDta-coated tubes or 
lithium-heparin-coated tubes. In agreement with asPa reg-
ulations, a maximum of 15 % blood volume was withdrawn 
in any 28-day period, with no more the 10 % withdrawn 
in any 24-h period. Blood samples were placed on ice for 
a maximum of 10 min before centrifugation at 4,000g 
for 15 min. Plasma samples were aliquoted out into indi-
vidual tubes; 15 μM of protease inhibitor cocktail (sigma-
aldrich, UK) was added to tubes containing plasma for 
vasopressin assay. all samples were snap-frozen on dry ice 
then stored at −80 °c.
Potential biomarker measurement
Arginine vasopressin
Vasopressin was extracted from the plasma, and the con-
centrations were measured by radioimmunoassay (RIa) 
(RB-319, Euro-Diagnostica aB, Malmö, sweden), as per 
kit instructions. this RIa has been previously validated for 
use with canine plasma (tidholm et al. 2005).
Cortisol
Plasma cortisol concentrations were measured by RIa 
(coat-a-count®, siemens, los angeles, ca, Usa), as per 
kit instructions, previously validated for use with canine 
plasma (Olsson et al. 2003).
Plasma creatinine measurement
Plasma creatinine was measured as a biomarker of acute 
kidney injury. Blood was collected by cephalic venepunc-
ture into lithium-heparin-coated tubes for dogs treated with 
cisplatin. a baseline sample was collected the day prior to 
cisplatin administration and further samples at weeks 1, 
2 (study 1 only) and 4 following cisplatin. samples were 
spun, and plasma was stored at −20 °c until analysis. 
Plasma creatinine was measured by IDEXX laboratories 
(Wetherby, UK) using a photometric method (Jaffe reac-
tion) (aU2700, Beckman coulter, high Wycombe, UK).
Granulocyte counts
Whole blood was collected as above on the day prior (base-
line) to cisplatin administration and at weeks 1, 2, 3 and 
4 following cisplatin. Granulocytes were counted using the 
animal blood cell counter calibrated for dog blood (scil 
animal care co., Viernheim, Germany). Dogs with granu-
locyte counts below 2.0 × 103/mm3 were considered to be 
neutropenic and received systemic antibiotic treatment to 
avoid septic complications (Vail 2009).
statistical analysis
all statistical analyses were carried out using PasW sta-
tistics 18 v 18.0.0 (sPss: an IBM company, chicago, Il, 
Usa). all data are presented as mean ± sEM, and signifi-
cance levels were set at P < 0.05.
Study 1: timecourses of nausea-like behavior and 
change in potential biomarkers were analyzed using a lin-
ear mixed-effect model with first-order autoregressive 
covariance structure. the statistical model included the 
fixed effects of treatment group, time and group × time 
interaction, the repeated effects of time and the random 
effect of subject. a least significant difference (lsD) post 
hoc pairwise comparison of placebo versus treatment was 
made at each time point if there was a significant interac-
tion between treatment and time.
the area under the curve (aUc) was calculated for 
timecourse of change in nausea-like behavior and potential 
biomarkers by determining the trapezoidal area under the 
curve. aUcs from different dose groups and the difference 
in the number of vomits were compared with an unpaired 
two-tailed t test.
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a univariate general linear model with lsD post hoc 
comparison was used to compare relative change from base-
line and differences between the two cisplatin treatment 
groups for plasma creatinine and granulocyte counts at each 
time point (weeks 1, 2, 4) following cisplatin administration.
Study 2: One-way aNOVa with tukey’s post hoc com-
parison was used to compare percentage change from base-
line in plasma creatinine and granulocyte counts firstly, 
within each period and secondly, for each time point 
(weeks 1, 2, 3 and 4) for all periods of the study.
Results
study 1: comparison of the clinical dose and low dose 
of cisplatin
No vomits were recorded for dogs treated with placebo in 
either period 1 or period 2. table 1 summarizes the char-
acteristic of the emetic response for to both doses of cis-
platin (onset, duration and number of events). the num-
ber of vomits was significantly different for the 2 doses of 
cisplatin (P = 0.03) (Fig. 2c). the latency to the onset of 
emetic effects of cisplatin was longer in dogs treated with 
the lower dose. the majority of vomits occurred between 4 
and 6 h following the low-dose cisplatin versus 2–4 h with 
the clinical (70 mg/m2) dose (Fig. 2a, b).
Nausea-like behavior Vas scores were significantly 
increased compared to placebo for both doses of cisplatin 
(Fig. 3a, b). table 1 summarizes the onset, duration and the 
peak nausea-like behavior response for both doses of cispl-
atin. the latency to the onset of nausea-like behavior was 
increased, and the peak score decreased for the low dose 
of cisplatin compared with the clinical (70 mg/m2) dose 
group. there was a 50 % reduction in the aUc of the low 
compared to the clinical dose of cisplatin, this was statisti-
cally significant (P = 0.03).
arginine vasopressin
Plasma aVP in the placebo-treated groups had the mean 
concentration of 1.78 ± 0.97 and 0.79 ± 0.10 pmol/l for 
periods 1 and 2, respectively. Plasma aVP was significantly 
increased compared with placebo for both doses of cispl-
atin (Fig. 4a, b). the onset, duration, peak time and concen-
tration of aVP is summarized in table 2. the timecourse of 
change in plasma aVP compared to that of emesis and nau-
sea-like behavior have a similar profile; however, the onset 
of the increase in plasma aVP concentrations appears to 
lag approximately 15 min behind increases in nausea-like 
behavior scores. the aUc0–7h of the low dose of cisplatin 
was reduced by 90 % when compared to the clinical dose; 
however, a statistical difference could not be demonstrated 
(P = 0.089).
cortisol
Plasma cortisol in the placebo-treated groups had the mean 
concentrations of 78.94 ± 11.77 and 139.44 ± 15.09 for 
periods 1 and 2, respectively. Plasma cortisol concentra-
tions were significantly increased compared to placebo for 
both the cisplatin dose groups (Fig. 5a,b). table 2 summa-
rizes the change in plasma cortisol for both doses of cispl-
atin. as seen with the vasopressin response, the profile of 
the timecourse of change in plasma cortisol mimics that of 
emesis and nausea-like behavior and the cortisol he onset 
lags 15 min behind increases in nausea-like behavior. there 
was a 40 % reduction in the aUc0–7h for the low compared 
to the clinical dose of cisplatin, this was not statistically 
significant (P = 0.218).
clinical safety monitoring
all dogs completed studies 1 and 2 with the exception of 
1 dog, which was removed from the last period of study 2. 
this female dog was withdrawn from the study due to the 
flaring of atopic dermatitis unrelated to cisplatin treatment 
(requiring the daily use of corticosteroids for treatment).
Plasma creatinine
Study 1: Plasma creatinine was significantly increased from 
baseline at only the 1-week time point for the clinical dose 
of cisplatin and at no time for the low dose of cisplatin. the 
Table 1  summary of the emetic and nausea responses following cisplatin administration
Nausea was recorded by a trained observer using a visual analogue scale (Vas) on a line from 0 to 100 mm based on the following nausea behav-
iors; salivation, lip licking, lethargy and restlessness; onset of vomiting and nausea-like behaviors estimated from visual inspection of the data
Dose Vomiting Nausea-like behaviors
Onset time  
(h)
Duration  
(h)
Mean number  
of vomits [range]
Onset time  
(h)
Duration  
(h)
Peak time  
(h)
Peak Vas 
(mean ± sEM)
70 mg/m2 Period 1 1.5 2.5 18 [8–32] 1.75 2.75 3.5 72 ± 16
15 mg/m2 Period 2 3.75 2 3.75 [0–6] 3.75 2.25 5.25 48 ± 4
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plasma creatinine level at week 1 was significantly lower 
in the low dose compared to the clinical dose (P = 0.002). 
(Fig. 6a). Results were available only from 3 dogs for the 
clinical dose cisplatin at 1 week following cisplatin treat-
ment. the plasma creatinine of one dog receiving the clini-
cal cisplatin dose increased from baseline by 59 µmol/l, the 
plasma creatinine of this dog subsequently normalized at 
week 2. Plasma creatinine did not increase by more than 
20 µmol/l from baseline for all other dogs in both studies 
1 and 2.
Study 2: Following repeated administration of cispl-
atin, no significant change in plasma creatinine was seen at 
any time point tested in each of the 4 periods of the study 
(Fig. 8a).
Granulocyte counts
Study 1: the granulocyte count at week 2 was significantly 
lower than the baseline (P = 0.005) following 70 mg/m2 
cisplatin (Fig. 6b). Granulocyte count had recovered by 
week 4. the decrease in granulocyte count at week 2 did 
not occur in group administered with the low dose of cis-
platin (P = 0.002). No significant changes from baseline 
were observed for the low dose.
In the 70 mg/m2 dose group, 3 out of 4 dogs developed 
neutropenia, the number of granulocytes dropped below 
2.0 × 103/mm3. clinical signs of sepsis (lethargy, inappe-
tence, pyrexia) were observed in 2 of the neutropenic dogs. 
the septic dogs received treatment with intravenous antibi-
otics (amoxicillin and clavulanic acid; augmentin, GsK, 
Middlesex, UK) and fluid therapy. Oral antibiotic treatment 
(Noroclav, Norbrook, Northhamptonshire, UK) was admin-
istered following the cessation of i.v. antibiotics and to the 
neutropenic dog that did not develop septic complications. 
Oral antibiotics were continued for a minimum of a week 
or until any clinical signs of sepsis had abated and granulo-
cyte counts had exceeded 2.0 × 103/mm3.
Study 2: there was no significant difference between 
baseline granulocyte counts for periods 1–4 of the study 
(Fig. 7). Granulocyte counts were compared to baseline for 
Fig. 2  study 1 (clinical vs. low dose), vomits: timecourse of vomits 
following 70 mg/m2 cisplatin i.v. (a) or 15 mg/m2 cisplatin i.v. (b). 
comparison of the mean number of vomits for the 70 and 15 mg/m2 
i.v. doses of cisplatin (c). Values expressed as mean ± sEM, n = 4 
per dose group. *significant difference between cisplatin dose groups 
(student’s t test P = 0.03)
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4 weeks following cisplatin administration in each period 
of the study (Fig. 8b). the only significant difference was 
observed in the 4th period of the study where relative 
change of granulocyte counts at week 3 was significantly 
lower than baseline following cisplatin administration 
(Fig. 8c). throughout the course of the study, the nadir of 
granulocytes occurred during week 3 of each period. the 
effect on granulocyte counts at 3 weeks seemed cumula-
tive, worsening with further administrations of cisplatin. 
During the nadir at week 3, 1 of 8 and 2 of 7 dogs became 
neutropenic periods 3 and 4 of the study, respectively. No 
clinical signs of sepsis were detected in any of the dogs that 
developed neutropenia in study 2, but prophylactic antibiot-
ics were given orally as described above for study 1.
Discussion
the first goal of the present study was to refine the dose of 
cisplatin used to induce nausea-like behavior and emesis in 
the dog as a model to test the anti-nausea and anti-emetic 
properties of pharmacological agents.
the data presented for study 1 demonstrated that the low 
dose of cisplatin (15 mg/m2) was associated with an 80 % 
reduction in the number of vomits making it a much more 
welfare friendly model in which to assess the efficacy of 
anti-nausea action of drugs. the dogs still demonstrated 
easily measurable signs of nausea-like behavior when com-
pared to the placebo, which was 33 % reduced compared 
to the clinical dose of cisplatin which has been tradition-
ally used. the latency to the onset of vomiting and nausea-
like behavior was greater in the low-dose cisplatin group as 
occurs in the ferret where latency to onset is significantly 
greater in studies utilizing 5 mg/kg cisplatin compared to 
those using 10 mg/kg (Percie du sert et al. 2011).
another goal of cisplatin dose refinement was to deter-
mine whether repeated administration of the low dose was 
acceptable from a toxicity perspective to allow a crosso-
ver design. three of the four dogs administered the clini-
cal dose of cisplatin (75 %) demonstrated neutropenia 
at a level that made the risk of infection very high, with 
50 % of dogs showing clinical signs of sepsis after a sin-
gle administration of cisplatin. this occurred after 2 weeks 
of cisplatin administration as would be expected based on 
the residual bone marrow reserve of white blood cells and 
the response time required for the regulation of neutrophil 
production (Dale et al. 1972). None of the dogs given the 
low dose of cisplatin showed neutropenia of this degree 
after a single dose. however, in study 2 where low-dose 
cisplatin was administered on four occasions separated by 
28 days, a progressive reduction in granulocyte count at 
week 3 was noted. the neutropenic threshold below which 
the risk of infection is known to increase significantly was 
only breached in 25 % of dogs receiving low-dose cisplatin 
after the fourth cycle and none of these dogs showed signs 
of sepsis. Ogilvie et al. (1988) reported a double nadir in 
granulocyte count at days 6 and 15 after administration of 
doses of 70 mg/m2 in healthy dogs. the nadirs we observed 
Fig. 3  study 1 (clinical vs. low dose), nausea-like behavior: time-
course of nausea-like behavior (Vas) following 70 mg/m2 cisplatin 
i.v. compared to placebo (a) or 15 mg/m2 cisplatin i.v. compared to 
placebo (b). comparison of the nausea-like behavior timecourse 
profiles for the 70 and 15 mg/m2 i.v. doses of cisplatin (c). Values 
presented as mean ± sEM, n = 4 per group. significant differences 
between cisplatin- and placebo-treated groups (mixed linear model, 
*P < 0.05, **P < 0.01, *** P < 0.001)
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were shifted to 7 and 21 days following administrations of 
the low dose cisplatin in study 2.
cisplatin also causes cumulative nephrotoxicity in clini-
cal patients given 70 mg/m2 repeatedly (Ogilvie et al. 1992). 
In the present study, all dogs were fluid loaded and pre-
treated with mannitol to protect them from the nephrotox-
icity of cisplatin. serial plasma creatinine concentrations 
were used to detect acute kidney injury induced by cisplatin. 
this marker is not the most sensitive marker of acute kid-
ney injury (aKI) as it is exponentially related to glomeru-
lar filtration rate (GFR), the gold standard for measuring 
functional renal mass (loor et al. 2013). Plasma creati-
nine concentration changed significantly in dogs receiving 
the clinical dose of cisplatin at week 1, and no significant 
increase in plasma creatinine concentration was determined 
over time in the dogs when they were given cisplatin repeat-
edly at the low dose. Ideally we would have measured GFR 
repeatedly following each dose of cisplatin administered. 
the technique for doing this was not compatible with the 
other procedures we wanted to conduct in the present study. 
alternatively, we could have monitored urinary markers of 
renal damage in the present study. Unfortunately, these have 
Fig. 4  study 1 (high vs. low dose), arginine vasopressin: timecourse 
of change in plasma aVP following 70 mg/m2 cisplatin i.v. compared 
to placebo (a) or 15 mg/m2 cisplatin i.v. compared to placebo (b). 
Values presented as mean ± sEM, n = 4 per group. significant dif-
ferences between cisplatin- and placebo-treated groups (mixed linear 
model, *P < 0.05, **P < 0.01, ***P < 0.001)
Table 2  summary of the biomarker responses following cisplatin administration
Onset of the increase in plasma vasopressin and cortisol was estimated by visual inspection of the data
Dose Vasopressin cortisol
Onset time 
(h)
Duration 
(h)
Peak time 
(h)
Peak concentration 
(pmol/l) (mean ± sEM)
Onset time 
(h)
Duration 
(h)
Peak time 
(h)
Peak concentration 
(nmol/l) (mean ± sEM)
70 mg/m2 Period 1 2 4 3.5 19.8 ± 5.8 2 4 3.5 456 ± 108.5
15 mg/m2 Period 2 4 3 6 4.2 ± 1.9 4 3 5 268 ± 46.8
Fig. 5  study 1 (clinical vs. low dose), cortisol: timecourse of change 
in plasma cortisol following 70 mg/m2 cisplatin i.v. compared to pla-
cebo (a) or 15 mg/m2 cisplatin i.v. compared to placebo (b). Values 
presented as mean ± sEM, n = 4 per group. significant differences 
between cisplatin- and placebo-treated groups (mixed linear model, 
*P < 0.05, **P < 0.01, ***P < 0.001)
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not been well characterized in the dog and the risk to the 
operators of collecting cisplatin-contaminated urine which 
would have been required to monitor changes in the urinary 
biomarkers over time was not considered to be justified.
Only one of the 4 dogs examined with the clinical dose 
of cisplatin showed an increase in plasma creatinine con-
centration that was of a magnitude that suggests aKI 
(>26.4 µmol/l) by the IRIs grading system (cowgill 2013). 
None of the 8 dogs given the 4 doses of cisplatin at the 
Fig. 6  study 1 (clinical vs. low dose), clinical monitoring: Percent-
age change from baseline of plasma creatinine (a) and granulocytes 
(b) following cisplatin treatment with 70 mg/m2 in period 1 or 15 mg/
m2 in period 2. Values presented as mean ± sEM, n = 4 per group. 
*significant difference between baseline and 1 week in the (univari-
ate general linear model P = 0.001). #significant differences between 
baseline, 1 week and 2 weeks in the 70 mg/m2 cisplatin group (uni-
variate general linear model P = 0.003 & 0.000, respectively). †sig-
nificant differences between cisplatin dose groups during week 2 
(univariate general linear model P = 0.000)
Fig. 7  study 2 (4 periods repeated administration), clinical monitor-
ing: comparison of baseline numbers of granulocytes at the baseline 
before each of the 4 periods of the study. Individual data presented 
with lines marking mean ± sEM
Fig. 8  study 2 (4 periods repeated administration), clinical monitor-
ing: percentage change from baseline of plasma creatinine (a) and 
granulocytes (b) following repeated administration of 18 mg/m2 cis-
platin treatment in periods 1–4 and comparison in the nadir granu-
locyte counts at 3 weeks for each period of study 2 (c). *significant 
difference between baseline and week 3 during period 4 (aNOVa, 
P = 0.017). #significant difference in granulocyte counts at the 
3 week time point between periods 1 and 4 of the study (aNOVa, 
P = 0.03)
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low-dose rate demonstrated such an increase. this would 
suggest that aKI is not detectable from a single dose at the 
high-dose rate or with repeated administration of the low-
dose rate. While accepting that the method used to detect 
aKI was not the most sensitive method and subclinical kid-
ney injury could have occurred in both dosing regimens, it 
seems likely that the saline and mannitol infusions used in 
the present study afforded sufficient renoprotection to avoid 
significant renal damage from cisplatin. that this remained 
the case even when the drug is administered repeatedly at 
the lower refined dose rate, suggesting this repeated dosing 
regimen could be used in studies with a crossover design 
without significant risk of serious renal damage.
Overall, these findings suggest that cisplatin could be 
used safely at the lower refined dose rate thus facilitating 
studies of a crossover design. Furthermore, with repeated 
administration, the characteristic nausea-like behavioral 
response did not vary for the number of doses administered 
(data not shown), suggesting this model is not only safe but 
repeatable and suited to the testing of the effects of novel 
anti-nausea and anti-emetic compounds.
the development of a model that allows repeated admin-
istration better reflects the situation in human medicine 
where repeated doses of chemotherapeutic agents are admin-
istered for cancer treatment. current animal models utilizing 
cisplatin produce a high frequency of emetic events. a meta-
analysis of the literature reported 107 ± 48 retches and vom-
its in ferrets treated with 10 mg/kg−1 cisplatin during a 4-h 
observation period. a biphasic response to 5 mg/m2 cisplatin 
was reported producing 105 ± 83 and 340 ± 171 retches and 
vomits in the acute and delayed phases, respectively (Per-
cie du sert et al. 2011). Dogs experienced between 13 and 
33 emetic events during the 6 h following administration of 
70 mg/m2 cisplatin (de la Puente-Redondo et al. 2007). the 
extent of vomiting induced by cisplatin in these models is not 
indicative of the situation in the clinic where emesis is well 
controlled by modern anti-emetic combinations (5-ht3 and 
NK1 antagonists) and nausea is now the most feared adverse 
effect of chemotherapy (de Boer-Dennert et al. 1997). For 
example, a complete response (no emesis and no rescue 
treatment) was achieved in 92 % of patients for 5 days fol-
lowing cisplatin administration, but nausea was still reported 
by 53.8 % of patients (Jang et al. 2013).
the second aim of this study was to identify putative 
biomarkers of nausea that might be used in drug develop-
ment to highlight compounds with nauseogenic potential at 
the preclinical drug development phase in an objective way. 
While the results from this study are not sufficient to iden-
tify aVP and cortisol as biomarkers of nausea, they can be 
described as correlates due to the similarities between the 
aVP and cortisol responses compared to behavioral nausea.
aVP secretion from the posterior pituitary gland is clas-
sically regulated physiologically by two main stimuli, high 
plasma osmolality (initial defense mechanism against dehy-
dration) and marked reduction in blood pressure (defense 
mechanism against severe hypotension threatening cNs 
arterial perfusion). the increases in aVP in dogs in study 1 
at t
-24h are likely to be associated with JVc placement and 
the related anesthesia and sedation, which occurred a few 
hours prior to the blood sample. aVP can be increased due 
to pain and surgical stress (Rose and Post 2001); however, 
this was a minimally invasive procedure. the nauseogenic 
effects of the sedative drugs (in particular alpha2 agonists) 
could provide the most likely explanation for the elevated 
aVP, which had returned to baseline noise level at the 
time of cisplatin administration. the significant increases 
in plasma aVP observed as a correlate of the behavioral 
response cannot be due to fluid imbalance from emesis as 
all dogs were fluid loaded with 0.9 % saline solution prior 
to cisplatin administration and received fluid replacement 
throughout the course of the study in excess of fluid lost in 
vomits. In dogs deprived of water to stimulate aVP secre-
tion, a pulsatile pattern of aVP release has been noted from 
baseline (van Vonderen et al. 2004). No evidence of pulsa-
tile secretion was found in plasma aVP increases induced 
by cisplatin, for either dose, and is therefore different to 
the response caused by fluid loss or hyperosmolarity. this 
suggests once again that the aVP secretion associated with 
nausea-like behavior is not likely to be due to physiologi-
cal responses associated with vomiting but could be related 
(directly or indirectly) to the nausea-like behavior, potential 
mechanisms discussed below.
the significant increase in plasma cortisol seen 
with both doses of cisplatin was unexpected. human 
patients undergoing cancer chemotherapy treatment have 
decreased serum cortisol concentrations (Morrow et al. 
2002). additionally, patients with low urinary cortisol 
prior to chemotherapy treatment experience more severe 
nausea (Fredrikson et al. 1992). this is perhaps a species 
difference; however, cortisol was not repeatedly measured 
in the above studies to produce a timecourse of cortisol 
change following chemotherapy administration so there 
may be increases in cortisol in humans that have not yet 
been characterized.
a possible mechanism for the role of correlates, aVP and 
cortisol, in nausea is that aVP is released from the hypo-
thalamus in response to emetic stimuli/stress to counteract 
potential water loss (Koch 1997). Increased aVP stimu-
lates the release of adrenocorticotropic hormone (acth) 
from the anterior pituitary, which in turn stimulates cortisol 
release from the adrenal cortex (chrousos and Gold 1998). 
the role of cortisol as a cause or effect of nausea is unclear. 
however, cortisol concentrations are controlled by a nega-
tive feedback system that includes the amygdala (chrousos 
and Gold 1998), an area of the brain involved in nausea sen-
sation (Napadow et al. 2013).
2695Exp Brain Res (2014) 232:2685–2697 
1 3
the relationship of ‘cause and effect’ between aVP 
and nausea is unclear. administration of exogenous aVP 
causes nausea (caras et al. 1997; Kim et al. 1997). the 
present study shows the onset of nausea behavior precedes 
increases in biomarkers aVP and cortisol. this suggests, at 
least for cisplatin-induced nausea, that aVP release is an 
effect of the onset of nausea.
From the current study, it cannot be determined whether 
biomarkers aVP and cortisol are correlates of nausea-like 
behavior alone or nausea-like behavior and emesis. the 
aUcs of aVP and cortisol, while not statistically significant 
possibly due to small sample size, did exhibit a dose-depend-
ent decrease for the 2 doses of cisplatin tested. the aUc of 
aVP displayed an 80 % decrease from the clinical to the low 
dose of cisplatin; the aUc of cortisol was reduced by 40 %. 
this is not proportional to the significant 50 % reduction in 
the nausea-like behavior aUc from the clinical to the low 
dose of cisplatin. the lack of proportionality in the changes 
in aUc would suggest that aVP and cortisol release is not 
directly dependent on the nausea-like behavior response. It is 
likely, especially in the case of aVP, that the emetic response 
is, at least partially, responsible for aVP release. to deter-
mine the suitability of aVP and cortisol as specific biomark-
ers of nausea, further experiment needs to be carried out ide-
ally in a model of nausea which does not induce emesis. Due 
to the current lack of a specific nausea model, the current 
cisplatin-induced model of nausea and emesis could be used 
with the administration of anti-emetic treatment to block the 
emetic response while leaving the nausea response.
two of the 3Rs are addressed by the low-dose cispl-
atin model of nausea and emesis. Firstly, ‘refinement’, 
the low dose still induces measurable nausea-like behav-
ior and emesis while improving animal welfare by reduc-
ing the extreme number of vomits and the toxicity caused 
by the clinical dose. secondly, ‘reduction’, reuse of the 
same cohort of animals in crossover studies designed with 
repeated administrations of cisplatin increases the statistical 
power of studies and reduces the number of dogs required. 
at the current time, ‘replacement’ is not a valid option for 
the study of nausea and emesis due to the complex physiol-
ogy involved. Recently the ameba, dictyostelium, has been 
found to be able to identify emetic compounds through 
a change in chemotactic behavior (Robery et al. 2011). 
however, this response does not identify all emetogenic 
compounds; dictyostelium did not have a respond to apo-
morphine or any of the cytotoxic compounds screened 
including cisplatin. the ameba may be useful in the future 
for the replacement of animals in the initial screening of 
the emetic potential of non-cytotoxic compounds, but, at 
the end of the day, the ameba nor any other cell can vomit 
so animal models are still required. as nausea is a subjec-
tive sensation, sentience is essential for it to be experienced 
necessitating the use of animal models. conditioned gaping 
is induced by the administration of emetogens to the rat 
(Parker and limebeer 2006). this model has been useful 
in the elucidation of nausea neural pathways (Parker and 
Mechoulam 2003; Rock et al. 2008; limebeer et al. 2010) 
in a common, cost-effective laboratory species. Ultimately, 
like cells, rats cannot vomit and the presence of nausea in 
a non-emetic species cannot be confirmed but this instead 
provides a model of a nausea-like response.
We recommend that the this model would be useful, not 
in the initial screening stages of compound testing, which 
could be carried out in more lower laboratory species such 
as the rat, but to determine the validity and translatability of 
nominated candidate compounds. the dog in particular is a 
good model for nausea and emesis in man as it is close to 
man in emetic sensitivity (andrews et al. 1990; Percie du 
sert et al. 2012), and therefore likely to have the greatest 
predictive validity of laboratory species. the unique nature 
of the human–canine bond has developed to allow humans 
to accurately predict the emotional state of the dog based 
on their facial expression (Bloom and Friedman 2013). this 
ability of dogs to communicate emotion to humans makes 
it a particularly relevant model for the study of a subjective 
sensation such as nausea. this communication was made 
more powerful in the present study by the steps taken by 
the investigators to acclimatize the dog to the experimental 
context and learn the individual characters of the dogs and 
how they respond to their environment. this led to an abil-
ity to detect and grade nausea-like behaviors in the dogs 
with a high level of sensitivity, which we contend would 
not be possible in species that do not bond with humans in 
the same way.
Conclusion
subclinical doses of cisplatin (15–18 mg/m2) induce sig-
nificant nausea-like behavior and emesis but with reduced 
toxicity. Increased safety achieved at these lower doses 
allows for crossover study designs, which include repeated 
administration of cisplatin in the same cohort of dogs. 
Plasma aVP and cortisol show potential as biomarkers of 
nausea; however, further studies are required to validate 
this finding fully.
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